Pharmaceutical

AD/PD 2024: exploring cutting-edge therapies for ALS

While some biotechs are attempting to develop disease-modifying therapies for amyotrophic lateral sclerosis (ALS), it has proven challenging.

Mar 9, 2024 - 18:00
AD/PD 2024: exploring cutting-edge therapies for ALS
While some biotechs are attempting to develop disease-modifying therapies for amyotrophic lateral sclerosis (ALS), it has proven challenging.
Read the original article

Tags:

Previous Article

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data

Next Article

FDA delays action on Lilly’s donanemab, intent on advisory committee meeting

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A new study shows how Medicaid coverage policies shape maternal health disparities

A new study shows how Medicaid coverage policies shape ...

Jul 18, 2023

Daiichi Sankyo receives Japan’s MHLW approval for VANFLYTA

Daiichi Sankyo receives Japan’s MHLW approval for VANFLYTA

May 26, 2023

Q2 2024 update: electronic medical record (emr) systems related private equity activity in the pharmaceutical industry

Q2 2024 update: electronic medical record (emr) systems...

Aug 7, 2024